Vijay Yadav And The Automation Of Clinical Trials With Digital Biomarkers

Clinical trials are something that is terribly crucial to the medical and healthcare sector, but they are plagued by challenges such as efficiency problems and high costs. The digitization of data has revolutionized the landscape of clinical trials, especially with the creation of digital biomarkers. 

Digital biomarkers often come in the form of edibles or more commonly, wearables. The birth of the digital health industry has made significant progress in addressing challenges faced by collecting and analyzing real-time data efficiently, leading to faster and more accurate results. Digital biomarkers can also reduce costs and increase confidence in the safety and efficacy of the drugs. Without digital biomarkers, it would mean a much longer process for life-saving drugs to be made available to the public. 

Vijay Yadav, Chief Technology Officer at Brooklyn Health, is one of the forerunners of digital biomarker integration for clinical trials and mentions that the work he is doing could be integral to the future of clinical trials. 

“Clinical trials have a propensity for error. By using digital biomarkers created through AI and machine learning, I offer a way to streamline clinical or remote clinical trial processes, reduce costs, and ultimately improve the outcomes for patients,” Yadav shares, stating that his one goal is to revolutionize the clinical trial industry before he moves on to even bigger things. 

When asked what those bigger things are, he reveals that “I want to lead efforts to establish open-source standards for digital biomarkers and collaborate with other industry leaders to ensure their widespread adoption.” 

Vijay hopes that in five years, he would have not only penetrated the global market, but be in collaboration with various healthcare providers and institutions to provide faster and more personalized care to patients through the incorporation of digital biomarkers into patient care protocols, stating that, “This could involve developing algorithms or other decision support tools to help healthcare providers interpret the data collected by digital biomarkers and make more informed treatment decisions.”

Aside from Vijay’s aspirations for digital biomarkers, he is also hoping to become more involved in the research and development division to expand the use of digital biomarkers beyond clinical trials, and playing a bigger part in chronic disease management and preventative care. Vijay’s passion for improving patient outcomes and his expertise in the area of medtech places him as a prime candidate for leading this innovation in the medical sector. 

But in the meantime, Vijay is excited to continue his work in the budding industry of digital biomarkers and seeing the vast improvements that it has brought to both clinical and remote clinical trials through real-time data collection whereby researchers are able to monitor patient progress and their behavior, enabling them to quickly determine if their patients are responding to the drug and adjusting the trial, medication, or other factors which will ultimately increase the likelihood of trial success and help bring new treatments to market much more quickly. 

Image sourced from Shutterstock

This post was authored by an external contributor and does not represent Benzinga's opinions. This post is for informational purposes only and not intended to be investing advice.